T. Rowe Price Investment Management Inc. Raises Stock Holdings in Elanco Animal Health Incorporated $ELAN

T. Rowe Price Investment Management Inc. boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,227,418 shares of the company’s stock after purchasing an additional 3,717,404 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 0.07% of Elanco Animal Health worth $797,197,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Teachers Retirement System of The State of Kentucky bought a new stake in Elanco Animal Health during the third quarter worth about $2,215,000. JPMorgan Chase & Co. grew its holdings in Elanco Animal Health by 266.4% in the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after purchasing an additional 1,394,839 shares during the period. Royce & Associates LP increased its stake in shares of Elanco Animal Health by 21.3% during the third quarter. Royce & Associates LP now owns 602,564 shares of the company’s stock valued at $12,136,000 after purchasing an additional 105,632 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Elanco Animal Health during the third quarter valued at approximately $1,876,000. Finally, Perbak Capital Partners LLP lifted its holdings in shares of Elanco Animal Health by 76.3% during the third quarter. Perbak Capital Partners LLP now owns 494,432 shares of the company’s stock valued at $9,958,000 after purchasing an additional 213,932 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 3.5%

Shares of NYSE:ELAN opened at $24.21 on Friday. The company has a market cap of $12.09 billion, a P/E ratio of -48.42, a PEG ratio of 1.53 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health Incorporated has a 1 year low of $13.15 and a 1 year high of $27.72. The stock’s fifty day moving average price is $22.99 and its 200-day moving average price is $23.49.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Rajeev A. Modi bought 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Leerink Partners upped their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. TD Cowen lifted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Morgan Stanley lifted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Finally, KeyCorp upped their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $28.55.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.